X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2707) 2707
Book Review (956) 956
Publication (230) 230
Book / eBook (51) 51
Book Chapter (32) 32
Newspaper Article (30) 30
Conference Proceeding (15) 15
Newsletter (15) 15
Dissertation (1) 1
Presentation (1) 1
Report (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2351) 2351
humans (1923) 1923
animals (1124) 1124
immunoglobulins (807) 807
immunology (771) 771
female (734) 734
male (621) 621
mice (529) 529
antibodies (465) 465
proteins (455) 455
immunoglobulin g (449) 449
middle aged (373) 373
monoclonal antibodies (363) 363
adult (359) 359
immunotherapy (349) 349
pharmacology & pharmacy (346) 346
antigens (329) 329
health aspects (325) 325
analysis (302) 302
research (291) 291
antibodies, monoclonal - therapeutic use (275) 275
medicine (248) 248
treatment outcome (246) 246
care and treatment (245) 245
aged (235) 235
cancer (227) 227
abridged index medicus (225) 225
oncology (222) 222
research article (222) 222
immunoglobulin g - immunology (218) 218
therapy (214) 214
allergy (204) 204
multidisciplinary sciences (200) 200
hematology (199) 199
monoclonal-antibody (196) 196
medicine, research & experimental (195) 195
clinical trials (188) 188
medical research (181) 181
science (178) 178
cytokines (177) 177
immunoglobulin e (172) 172
inflammation (172) 172
enzyme-linked immunosorbent assay (170) 170
immunoglobulins, intravenous - therapeutic use (167) 167
biotechnology & applied microbiology (164) 164
lymphocytes (162) 162
patients (158) 158
double-blind (157) 157
tumors (156) 156
expression (155) 155
disease (154) 154
drug therapy (153) 153
intravenous immunoglobulin (153) 153
immune system (152) 152
in-vivo (149) 149
vaccines (149) 149
immunization (148) 148
review (148) 148
antibodies, monoclonal - immunology (147) 147
medicine & public health (146) 146
t cells (144) 144
disease models, animal (143) 143
immunoglobulin g - therapeutic use (143) 143
physiological aspects (141) 141
immunogenicity (139) 139
rheumatoid arthritis (139) 139
recombinant fusion proteins - therapeutic use (135) 135
immune response (133) 133
viral antibodies (133) 133
safety (131) 131
biological products (129) 129
cytotoxicity (128) 128
article (127) 127
biochemistry & molecular biology (127) 127
biology (127) 127
infections (127) 127
mice, inbred balb c (127) 127
monoclonal-antibodies (126) 126
etanercept (125) 125
tumor necrosis factor-alpha - antagonists & inhibitors (125) 125
antibody (123) 123
infliximab (123) 123
studies (123) 123
internal medicine (122) 122
immunoglobulin fab fragments - therapeutic use (121) 121
adolescent (119) 119
infectious diseases (119) 119
peptides (119) 119
immunoglobulin e - immunology (118) 118
rheumatoid-arthritis (118) 118
autoimmunity (117) 117
immunoglobulin g - blood (116) 116
binding (115) 115
cells (111) 111
rheumatology (110) 110
pharmacokinetics (108) 108
dendritic cells (107) 107
efficacy (107) 107
gene expression (107) 107
immunoglobulin (107) 107
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (37) 37
Online Resources - Online (2) 2
UofT at Mississauga - Stacks (2) 2
UofT at Scarborough - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
UTL at Downsview - May be requested (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2804) 2804
French (7) 7
German (5) 5
Spanish (4) 4
Russian (2) 2
Chinese (1) 1
Japanese (1) 1
Romanian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2159 - 2167
OBJECTIVE To compare the efficacy and safety of dulaglutide, a once-weekly GLP-1 receptor agonist, with placebo and exenatide in type 2 diabetic patients. The... 
GLYCEMIC CONTROL | GLUCAGON-LIKE PEPTIDE-1 | EXENDIN-4 | SITAGLIPTIN | ENDOCRINOLOGY & METABOLISM | ANALOG LIRAGLUTIDE | OPEN-LABEL | LY2189265 | TREATED PATIENTS | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Male | Immunoglobulin Fc Fragments - administration & dosage | Thiazolidinediones - administration & dosage | Metformin - adverse effects | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Metformin - administration & dosage | Drug Therapy, Combination | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Venoms - adverse effects | Hypoglycemia - drug therapy | Thiazolidinediones - adverse effects | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Type 2 diabetes | Care and treatment | Safety and security measures | Dosage and administration | Metformin | Comparative analysis | Exenatide | Clinical trials | Hemoglobin | Diabetes | Product safety | Drug dosages | Placebo effect | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9951, pp. 1349 - 1357
Summary Background Dulaglutide and liraglutide, both glucagon-like peptide-1 (GLP-1) receptor agonists, improve glycaemic control and reduce weight in patients... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | GLYCEMIC CONTROL | EFFICACY | PHYSICAL-ACTIVITIES | SAFETY | PARALLEL-GROUP | EXENATIDE | ANALOG LIRAGLUTIDE | GATEKEEPING PROCEDURES | DAILY LIVING QUESTIONNAIRE | PEPTIDE-1 RECEPTOR AGONISTS | Metformin - therapeutic use | Glucagon-Like Peptide 1 - administration & dosage | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Immunoglobulin Fc Fragments - administration & dosage | Hypoglycemic Agents - administration & dosage | Fasting - blood | Female | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Treatment Outcome | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Analysis of Variance | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Type 2 diabetes | Usage | Research | Comparative analysis | Drug therapy | Clinical trials | Enzymes | Blood pressure | Diabetes | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 06/2015, Volume 13, Issue 6, pp. 967 - 977
Prophylactic factor replacement, which prevents hemarthroses and thereby reduces the musculoskeletal disease burden in children with hemophilia A, requires... 
coagulation factor | hemophilia A | recombinant fusion proteins | VIII | children | prophylaxis | Children | Coagulation factor VIII | Recombinant fusion proteins | Hemophilia A | Prophylaxis | Recombinant Fusion Proteins - immunology | Factor VIII - immunology | Hemarthrosis - diagnosis | Age Factors | Recombinant Fusion Proteins - adverse effects | Factor VIII - pharmacokinetics | Humans | Child, Preschool | Half-Life | Male | Immunoglobulin Fc Fragments - administration & dosage | North America | Hemarthrosis - blood | Immunoglobulin Fc Fragments - immunology | China | Coagulants - administration & dosage | Factor VIII - adverse effects | Female | Hemophilia A - prevention & control | Coagulants - pharmacokinetics | Hemophilia A - diagnosis | Child | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Severity of Illness Index | Drug Administration Schedule | Europe | Risk Factors | Treatment Outcome | Hemophilia A - blood | Hemarthrosis - drug therapy | Recombinant Fusion Proteins - pharmacokinetics | Factor VIII - administration & dosage | South Africa | Infusions, Intravenous | Australia | Coagulants - adverse effects | Coagulants - immunology | Hemarthrosis - prevention & control | Hemophilia A - drug therapy | Antibodies, Neutralizing - blood | Prevention | Proteins | Care and treatment | Blood coagulation factor VIII | Hemophilia | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 03/2012, Volume 119, Issue 13, pp. 3031 - 3037
Journal Article
Circulation, ISSN 0009-7322, 05/2011, Volume 123, Issue 17, pp. 1891 - 1899
Background-Blocking of glycoprotein VI-dependent pathways by interfering in vascular collagen sites is commonly seen as an attractive target for an... 
stroke | platelet aggregation inhibitors | platelet adhesion | glycoprotein VI | platelet aggregation | CARDIAC & CARDIOVASCULAR SYSTEMS | FAB FRAGMENT | THROMBUS FORMATION | ACUTE CORONARY SYNDROME | ADHESION | CLOPIDOGREL | IN-VIVO | PERIPHERAL VASCULAR DISEASE | SOLUBLE GPVI | MICE | HEMATOLOGY | ANTITHROMBOTIC PROTECTION | EXPRESSION | Injections, Intravenous | Cricetulus | Recombinant Fusion Proteins - adverse effects | Humans | Male | Immunoglobulin Fc Fragments - administration & dosage | Dose-Response Relationship, Drug | Young Adult | Platelet Aggregation Inhibitors - administration & dosage | Platelet Membrane Glycoproteins - administration & dosage | Adult | Platelet Membrane Glycoproteins - adverse effects | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | CHO Cells | Platelet Aggregation Inhibitors - adverse effects | Hemostasis - drug effects | Platelet Membrane Glycoproteins - pharmacokinetics | Cricetinae | Glycoproteins - administration & dosage | Collagen - administration & dosage | Animals | Platelet Count | Recombinant Fusion Proteins - pharmacokinetics | Aggregation | Safety and security measures | Blood platelets | Hemostasis | Patient outcomes | Atherosclerosis | Dosage and administration | Research | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2168 - 2176
Journal Article
Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2149 - 2158
OBJECTIVE To compare the efficacy and safety of two doses of once-weekly dulaglutide, a glucagon-like peptide 1 receptor agonist, to sitagliptin in... 
METFORMIN | GLYCEMIC CONTROL | PLACEBO | GLP-1 | GLUCAGON-LIKE PEPTIDE-1 | RECEPTOR AGONISTS | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | ANALOG LIRAGLUTIDE | OPEN-LABEL | INHIBITOR SITAGLIPTIN | Glycated Hemoglobin A - analysis | Triazoles - administration & dosage | Triazoles - adverse effects | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Pyrazines - administration & dosage | Male | Immunoglobulin Fc Fragments - administration & dosage | Dose-Response Relationship, Drug | Hypoglycemic Agents - administration & dosage | Female | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Double-Blind Method | Treatment Outcome | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Pyrazines - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Glucagon-Like Peptide 1 - therapeutic use | Type 2 diabetes | Sitagliptin | Care and treatment | Dosage and administration | Safety and security measures | Comparative analysis | Clinical trials | Hemoglobin | Glycosylation | Diabetes | Product safety | Placebo effect | Index Medicus | Psychosocial Research | Nutrition | Education | Clinical Care
Journal Article
The Lancet Oncology, ISSN 1470-2045, 10/2017, Volume 18, Issue 10, pp. 1338 - 1347
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 11/2014, Volume 12, Issue 11, pp. 1788 - 1800
BackgroundRoutine prophylaxis with replacement factorVIII (FVIII) - the standard of care for severe hemophiliaA - often requires frequent intravenous infusions... 
Drug | Administration schedule | Pharmacokinetics | Recombinant fusion proteins | Hemophilia A | Factor VIII | SEVERE HEMOPHILIA-A | SAFETY | PROLONGED ACTIVITY | CARE | drug | factorVIII | PROPHYLACTIC TREATMENT | recombinant fusion proteins | BLOOD-GROUP | ON-DEMAND | pharmacokinetics | PERIPHERAL VASCULAR DISEASE | administration schedule | hemophiliaA | COAGULATION-FACTOR VIII | HEMATOLOGY | PRACTICE PATTERNS | Recombinant Fusion Proteins - adverse effects | Factor VIII - pharmacokinetics | Humans | Half-Life | Male | Hemorrhage - prevention & control | Immunoglobulin Fc Fragments - administration & dosage | Young Adult | Time Factors | Computer Simulation | Coagulants - administration & dosage | Adult | Factor VIII - adverse effects | Coagulants - pharmacokinetics | Hemophilia A - diagnosis | Immunoglobulin Fc Fragments - adverse effects | Immunoglobulin Fc Fragments - blood | Recombinant Fusion Proteins - administration & dosage | von Willebrand Factor - metabolism | Hemostasis - drug effects | Severity of Illness Index | Drug Administration Schedule | Treatment Outcome | Biomarkers - blood | Coagulants - blood | Hemophilia A - blood | Recombinant Fusion Proteins - blood | Models, Biological | Recombinant Fusion Proteins - pharmacokinetics | Adolescent | Factor VIII - administration & dosage | Hemorrhage - chemically induced | Infusions, Intravenous | Coagulants - adverse effects | Drug Monitoring | Hemophilia A - drug therapy | Proteins | Blood coagulation factor VIII | Analysis | Von Willebrand factor | Hemophilia | Index Medicus
Journal Article
Hypertension, ISSN 0194-911X, 10/2014, Volume 64, Issue 4, pp. 731 - 737
Glucagon-like peptide-1 receptor agonists, used to treat type 2 diabetes mellitus, are associated with small reductions in systolic blood pressure (SBP) and... 
Heart rate | Hypertension | Glucagon-like peptide-1 | Blood pressure monitoring | Dulaglutide | Blood pressure | Ambulatory | Type 2 diabetes mellitus | blood pressure | heart rate | ANALOG | AMIDE | glucagon-like peptide-1 | dulaglutide | blood pressure monitoring, ambulatory | BIOLOGY | type 2 diabetes mellitus | DOUBLE-BLIND | PERIPHERAL VASCULAR DISEASE | LY2189265 | SECRETION | hypertension | Nausea - chemically induced | Recombinant Fusion Proteins - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Male | Diarrhea - chemically induced | Heart Rate - drug effects | Injections, Subcutaneous | Heart Rate - physiology | Female | Blood Pressure - drug effects | Blood Pressure - physiology | Immunoglobulin Fc Fragments - therapeutic use | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Double-Blind Method | Drug Administration Schedule | Treatment Outcome | Glucagon-Like Peptides - adverse effects | Vomiting - chemically induced | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - physiopathology | Glucagon-Like Peptide-1 Receptor | Aged | Glucagon-Like Peptides - therapeutic use | Blood Pressure Monitoring, Ambulatory | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Index Medicus
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 07/2017, Volume 19, Issue 7, pp. 953 - 961
Aims: To compare adherence (proportion of days covered [PDC]), persistence, and treatment patterns among patients with type 2 diabetes mellitus (T2DM) newly... 
glucagon‐like peptide‐1 receptor agonists | switching | real‐world evidence | adherence | type 2 diabetes mellitus | persistence | augmentation | real-world evidence | glucagon-like peptide-1 receptor agonists | STATEMENT | MANAGEMENT | PROPENSITY SCORE | HEALTH-CARE COSTS | IMPACT | THERAPY | ENDOCRINOLOGY & METABOLISM | INHIBITORS | OUTCOMES | ASSOCIATION | MEDICATION ADHERENCE | Follow-Up Studies | Recombinant Fusion Proteins - adverse effects | United States | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Male | Practice Patterns, Physicians | Diabetes Mellitus, Type 2 - metabolism | Immunoglobulin Fc Fragments - administration & dosage | Peptides - administration & dosage | Glucagon-Like Peptide-1 Receptor - metabolism | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Immunoglobulin Fc Fragments - therapeutic use | Retrospective Studies | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Hypoglycemic Agents - therapeutic use | Drug Administration Schedule | Venoms - adverse effects | Kaplan-Meier Estimate | Drug Prescriptions | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Medication Adherence | Liraglutide - adverse effects | Liraglutide - therapeutic use | Venoms - therapeutic use | Aged | Glucagon-Like Peptides - therapeutic use | Liraglutide - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Drug Monitoring | Hypoglycemic Agents - adverse effects | Glucagon-Like Peptide-1 Receptor - agonists | Peptides - adverse effects | Peptides - therapeutic use | Cohort Studies | Type 2 diabetes | Care and treatment | Hypoglycemic agents | Glucagon | Comparative analysis | Diabetes therapy | Patients | Patient compliance | Diabetes | Index Medicus | Original
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2018, Volume 13, Issue 5, pp. e0196422 - e0196422
Nectin-2 is a transmembrane glycoprotein which is involved in the process of Ca2+-independent cell-cell adhesion. In our previous study, we have demonstrated... 
IMMUNE-MECHANISMS | TIGHT JUNCTIONS | INTRAVENOUS IMMUNOGLOBULIN-G | GAMMA-RI | MULTIDISCIPLINARY SCIENCES | HUMAN-IGG | BINDING-SITE | NECTIN | CELL-CELL ADHESION | PVR CD155 | V-DOMAIN | Humans | Antibodies, Monoclonal - adverse effects | Macaca fascicularis | Male | Recombinant Proteins - adverse effects | Immunoglobulin Fc Fragments - immunology | Nectins - genetics | Protein Engineering | Female | Antibodies, Monoclonal - immunology | Immunoglobulin Fc Fragments - adverse effects | Nectins - antagonists & inhibitors | Antibody-Dependent Cell Cytotoxicity | Thrombocytopenia - etiology | Recombinant Proteins - genetics | Mice, SCID | Xenograft Model Antitumor Assays | Antibodies, Monoclonal - genetics | Animals | Recombinant Proteins - immunology | Nectins - immunology | Cell Line, Tumor | Thrombocytopenia - prevention & control | Mice | Immunoglobulin Fc Fragments - genetics | Physiological aspects | Glycoproteins | Monkeys | Research | Gene expression | Immunohistochemistry | Animal models | Ovarian carcinoma | Calcium | Laboratories | Toxicity | Xenotransplantation | Immunoglobulin G | Cytotoxicity | Macrophages | Ovarian cancer | Cell adhesion & migration | Anticancer properties | Phagocytes | Immunology | Antitumor agents | Safety engineering | Liabilities | Cell adhesion | Toxicity testing | Xenografts | Biocompatibility | Safety | Pharmaceutical industry | Pharmaceutical sciences | Thrombocytopenia | Immunoglobulins | Glycoprotein | Breast cancer | Mitigation | Nectin | Monoclonal antibodies | Platelets | Phagocytosis | Calcium ions | Cancer | Tumors | Index Medicus
Journal Article